米国の小児心臓病市場規模・予測、世界・地域別シェア、動向、成長機会分析レポート：製品タイプ別、手技別、エンドユーザー別、適応疾患別、国別

米国の小児心臓病市場規模は、2023年の25億4,000万米ドルから2031年には35億9,000万米ドルに達すると予測されています。2023～2031年のCAGRは4.4%と予測されます。

小児心臓病学は、乳幼児、小児、青少年の心臓疾患の診断、治療、管理に焦点を当てた医学の専門分野です。この分野では、心室中隔欠損症、心房中隔欠損症、外科的介入を必要とする複雑な問題など、さまざまな先天性（出生時に存在する）および後天性の心臓疾患を扱う。

各社の戦略的取り組み

米国の小児心臓病市場に参入している企業は、製品承認、提携、資金調達、契約、新製品発売などの戦略的開発に常に注力しており、これにより売上高、地理的リーチ、幅広い顧客層に対応する能力を高めています。米国の小児心臓病市場で事業を展開する主要企業が行った戦略的イニシアチブを以下にいくつか紹介する：

2024年1月、Occlutech社は心房中隔欠損症（ASD）治療用のOcclutech Pistol PusherとOcclutech ASD Occluderについて米国食品医薬品局（FDA）の承認を取得しました。この承認により、オクルーテックは販売代理店であるB. Braun Interventional Systems Inc.との独占的パートナーシップのもと、直ちに商業化を開始します。オクルテックASDオクルーダーは、ニチノール製の自己拡張型ダブルディスク閉塞デバイスで、2枚の傘状のフレキシブルディスクからなり、2枚のディスクの中央にはウエストがあり、2枚のディスクを連結しています。

2023年2月、メドトロニックはハーモニー経カテーテル肺動脈弁（TPV）システムをリニューアル発売しました。このシステムは、先天性心疾患で右室流出路（RVOT）がもともとある患者や手術で修復された患者を対象に、開心術に代わる低侵襲の治療法です。このシステムは、肺に送り込まれた血液が心臓の右下室に漏れる重度の肺動脈弁閉鎖不全症も発症するRVOT異常を患う患者のために設計されました。

2022年5月、オクルーテックはB. Braun Interventional Systems Inc（BIS）と独占販売契約を締結しました。BISは、オクルーテックの世界チームの支援を受けて、オクルーテックのFlex II ASD Occluderの米国での商業化活動を開始します。この提携により、オクルーテックは戦略的に重要な米国市場で成功を収めることになります。また、BISは、先天性心臓と構造性心臓に焦点を当てることで、ポートフォリオの関連性を高めています。

そのため、小児心臓病機器の開発に注力するさまざまな企業による戦略的イニシアチブは、今後数年間、米国の小児心臓病市場に成長機会をもたらす可能性が高いです。

しかし、熟練した小児心臓病専門医が少ないことが、心血管疾患を持つ小児に対するケアの可用性と質に影響を与えています。先天性心疾患やその他の心疾患の発生率が上昇を続ける中、専門的な心臓病学サービスに対する需要は、訓練を受けた専門家の供給を上回っています。さらに、出生直後の長期的な小児心臓病疾患に対処するための予防的循環器科医療に対する認識も高まっています。米国の小児科学会によると、小児心臓病専門医の不足は顕著であり、特に米国の農村部や十分なサービスを受けていない地域では、専門医療へのアクセスが制限されていることが多いです。米国の小児科学会（ABP）の2023年6月までのデータによると、これまでに4,117人の小児心臓病専門医が認定を受けており、そのうち3,096人（75％）が認定維持（MOC）に積極的に登録しています。米国に限定すると、2023年には1州あたり平均57.3人（範囲0～329人）の認定小児心臓病専門医がおり、これは米国全体で17歳までの小児10万人あたり4人（範囲0.0～25.4人）の循環器専門医がいることになります。州内の小児心臓病専門医の分布には大きなばらつきがあり、多くは都市部に集中し、農村部にはほとんどいないです。小児心臓病専門医の不足はまた、既存の開業医へのプレッシャーを増大させ、燃え尽き症候群や仕事への不満につながっています。このような状況は、最終的に患者の転帰に影響を及ぼす可能性があります。過重労働の専門医は、複雑な症例に必要な包括的治療を提供できない可能性があるからです。このように、熟練した小児心臓病専門医が少ないことが市場成長の妨げとなっています。

エンドユーザーに基づく洞察

エンドユーザーに基づき、小児心臓病市場は病院、専門クリニック、その他に分類されます。2023年には病院セグメントが市場を独占しました。米国の小児心臓病市場において、病院セグメントは心血管疾患を患う小児に専門的なケアを提供するという点で重要です。先天性心疾患やその他の心臓病の症例が増加しているため、包括的治療のための最新技術と集学的チームを備えた小児心臓センターが増加しています。ボストン小児病院、テキサス小児病院、シアトル小児病院、フィラデルフィア小児病院は、小児心臓病学に対する最先端の設備と革新的なアプローチ（低侵襲手術技術や介入手技を含む）を誇り、そのリーダー的存在として知られています。これらの病院では、循環器専門医が他の外科医、麻酔科医、看護スタッフと協力して最適な治療結果が得られるよう、共同治療を重視しています。シアトル小児病院では、2023年に約570件の小児心臓手術を行った。遠隔医療と遠隔モニタリング技術への最近の投資は、地方にいる患者にとって非常に必要な常時ケアとフォローアップにより、患者管理をさらに強化しています。医療システムで強化された専門的治療と治療プロトコルへのアクセスは、病院セグメントの成長と小児心臓病学の進歩を保証し、心血管疾患に苦しむ若年患者の生活の質を向上させる。

米国心臓病学会、Children's Heart Foundation、米国疾病予防管理センター、米国食品医薬品局、米国の小児科学会などは、米国の小児心臓病市場レポート作成時に参照した一次情報および二次情報の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

• 主要な洞察

第3章 調査手法

• 2次調査
• 1次調査
  • 仮説の策定
  • マクロ経済要因分析
  • 基礎数値の作成
  • データの三角測量
  • 国レベルのデータ

第4章 米国の小児心臓病市場情勢

• PEST分析
• 米国のステルノトミー手技分析

第5章 米国の小児心臓病市場-主要市場力学

• 米国の小児心臓病市場- 主要市場力学
• 市場促進要因
  • 小児科における先天性心疾患の発生率の増加
  • 低侵襲手技へのシフトの高まり
• 市場抑制要因
  • 熟練した小児心臓病専門医の不足
• 市場機会
  • 企業による戦略的取り組み
• 今後の動向
  • AIおよび機械学習と小児心臓病学の統合
• 促進要因と抑制要因の影響

第6章 米国の小児心臓病市場分析

• 米国の小児心臓病市場売上高, 2021-2031年

第7章 米国の小児心臓病市場の分析：製品タイプ別

• 経カテーテル心臓弁
• 咬合デバイス
• アテレクトミーデバイス
• カテーテル
• ステント
• イントロデューサーシース
• その他

第8章 米国の小児心臓病市場分析：手技別

• インターベンション手技
• 心臓リズム管理手技
• その他

第9章 米国の小児心臓病市場の分析：エンドユーザー別

• 病院
• 専門クリニック
• その他

第10章 米国の小児心臓病市場の分析：適応疾患別

• 卵円孔（PFO）
• 先天性心疾患
• 後天性心疾患
• 不整脈
• 心筋症
• その他

第11章 業界情勢

• 米国の小児心臓病市場における成長戦略
• 有機的成長戦略
• 無機的成長戦略

第12章 企業プロファイル

• Abbott Laboratories
• Medtronic Plc
• Edwards Lifesciences Corp
• Terumo Corp
• W L Gore and Associates Inc
• NuMED
• Cordis Corp
• Occlutech US LLC
• Biotronik SE & Co KG
• RENATA MEDICAL

第13章 付録

List Of Tables

• Table 1. US Pediatric Cardiology Market Segmentation
• Table 2. US Pediatric Cardiology Market - Volume and Forecast to 2031 (Units) - by Product Type
• Table 3. US Pediatric Cardiology Market - Volume and Forecast to 2031 (Units) - by Surgical Procedures
• Table 4. US Pediatric Cardiology Market - Volume and Forecast to 2031 (Units) - by Disease Indication
• Table 5. Recent Organic Growth Strategies in US Pediatric Cardiology Market
• Table 6. Recent Inorganic Growth Strategies in the US Pediatric Cardiology Market
• Table 7. Glossary of Terms, US Pediatric Cardiology Market

List Of Figures

• Figure 1. US Pediatric Cardiology Market Segmentation, by Country
• Figure 2. PEST Analysis
• Figure 3. Impact Analysis of Drivers and Restraints
• Figure 4. US Pediatric Cardiology Market Revenue (US$ Million), 2021-2031
• Figure 5. US Pediatric Cardiology Market Share (%) - by Product Type, 2023 and 2031
• Figure 6. Transcatheter Heart Valves: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 7. Occlusion Devices: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 8. Atherectomy Devices: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 9. Catheters: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 10. Stents: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 11. Introducer Sheaths: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 12. Others: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 13. US Pediatric Cardiology Market Share (%) - by Surgical Procedures, 2023 and 2031
• Figure 14. Interventional Procedures: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 15. Heart Rhythm Management Procedures: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 16. Others: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 17. US Pediatric Cardiology Market Share (%) - by End User, 2023 and 2031
• Figure 18. Hospitals: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 19. Specialty Clinics: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 20. Others: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 21. US Pediatric Cardiology Market Share (%) - by Disease Indication, 2023 and 2031
• Figure 22. Patient Foramen Ovale (PFO): US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 23. Congenital Heart Disease: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 24. Acquired Heart Disease: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 25. Arrhythmias: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 26. Cardiomyopathies: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 27. Others: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 28. Growth Strategies in US Pediatric Cardiology Market

The US pediatric cardiology market size is projected to reach US$ 3.59 billion by 2031 from US$ 2.54 billion in 2023. The market is expected to register a CAGR of 4.4% during 2023-2031.

Pediatric cardiology is a specialized branch of medicine that focuses on diagnosing, treating, and managing heart conditions in infants, children, and adolescents. This field addresses a range of congenital (present at birth) and acquired heart defects, including conditions like ventricular septal defects, atrial septal defects, and more complex issues requiring surgical intervention.

Strategic Initiatives by Companies

Companies operating in the US pediatric cardiology market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them boost their sales, geographic reach, and capacities to cater to a wide customer base. A few strategic initiatives taken by key players operating in the US pediatric cardiology market are mentioned below:

In January 2024, Occlutech received the United States Food and Drug Administration (FDA) for Occlutech Pistol Pusher and Occlutech ASD Occluder for the treatment of atrial septal defects (ASD). With this approval, Occlutech will immediately commence commercialization in an exclusive partnership with distributor B. Braun Interventional Systems Inc. The Occlutech ASD occluder is a nitinol, self-expanding, double-disc occlusion device that comprises two umbrella-shaped flexible discs with a waist in the middle connecting the two discs.

In February 2023, Medtronic relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT). The system was designed for patients suffering from RVOT anomalies who also develop severe pulmonary valve regurgitation, a condition where blood leaks into the right lower chamber of the heart after being pumped into the lungs.

In May 2022, Occlutech signed an exclusive distribution agreement with B. Braun Interventional Systems Inc (BIS). BIS will initiate the US commercialization activities for Occlutech's Flex II ASD Occluder with the support of the global Occlutech team. Through this collaboration, Occlutech records success in the strategically important US market, which is characterized as a premier and commercially attractive healthcare system. Also, BIS increases its portfolio's relevancy through strong congenital and structural heart focus.

Therefore, strategic initiatives by various companies focusing on the development of pediatric cardiology devices are likely to offer growth opportunities to the US pediatric cardiology market in the coming years.

However, the dearth of skilled pediatric cardiologists is impacting the availability and quality of care for children with cardiovascular conditions. As the incidence of congenital heart defects and other cardiac diseases continues to rise, the demand for specialized cardiology services is outpacing the supply of trained professionals. In addition, there is increasing awareness about preventive cardiology care to address long-term pediatric cardiology disorders immediately after birth. According to the American Academy of Pediatrics, there is a notable shortage of pediatric cardiologists, particularly in rural and underserved areas in the US, where access to specialized care is often limited. Based on the American Board of Pediatrics (ABP) data through June 2023, 4,117 pediatric cardiologists have ever been board-certified, of which 3,096 (75%) were actively enrolled in Maintenance of Certification (MOC). When the workforce is limited to the US, there was an average of 57.3 board-certified pediatric cardiologists per state (range 0-329) in 2023, which accounts for 4 cardiologists per 100,000 children aged to 17 years (range 0.0-25.4) across the US. There was wide variability in the distribution of pediatric cardiologists within states, with most concentrated in urban settings and few in rural areas. The shortage of pediatric cardiologists also contributes to increased pressure on existing practitioners, leading to burnout and job dissatisfaction. This situation can ultimately affect patient outcomes, as overworked specialists might not be able to provide the comprehensive care needed for complex cases. Thus, the dearth of skilled pediatric cardiologists hampers the market growth.

End User-Based Insights

Based on end users, the pediatric cardiology market is categorized into hospitals, specialty clinics, and others. The hospitals segment dominated the market in 2023. In the US pediatric cardiology market, the hospitals segment is significant in terms of delivering specialized care to children suffering from cardiovascular disorders. The increasing cases of congenital heart defects and other heart diseases have elevated pediatric cardiac centers with modern technologies and multidisciplinary teams for comprehensive treatment. Boston Children's Hospital, Texas Children's Hospital, Seattle Children's Hospital, and the Children's Hospital of Philadelphia are among the acknowledged leaders, boasting state-of-the-art facilities and innovative approaches to pediatric cardiology-including minimally invasive surgical techniques and interventional procedures. These hospitals emphasize collaborative care, where a cardiologist works with other surgeons, anesthesiologists, and nursing staff to ensure optimized treatment results. Seattle Children's Hospital performed ~570 pediatric heart surgeries in 2023. Recent investments in telemedicine and remote monitoring technologies further enhance patient management, with constant care and follow-up, highly necessary for patients located in rural areas. Access to specialized care and treatment protocols enhanced in health systems ensures growth in the hospitals segment and advancements in pediatric cardiology, which will improve the quality of life for young patients suffering from cardiovascular problems.

American College of Cardiology, Children's Heart Foundation, Centers for Disease Control and Prevention, United States Food and Drug Administration, and American Academy of Pediatrics are among the primary and secondary sources referred to while preparing the US pediatric cardiology market report.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. US Pediatric Cardiology Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
• 4.3 US Sternotomy Procedure Analysis

5. US Pediatric Cardiology Market - Key Market Dynamics

• 5.1 US Pediatric Cardiology Market - Key Market Dynamics
• 5.2 Market Drivers
  • 5.2.1 Increasing Incidence of Congenital Heart Disease in Pediatrics
  • 5.2.2 Growing Shift Toward Minimally Invasive Procedures
• 5.3 Market Restraints
  • 5.3.1 Dearth of Skilled Pediatric Cardiologists
• 5.4 Market Opportunities
  • 5.4.1 Strategic Initiatives by Companies
• 5.5 Future Trends
  • 5.5.1 Integration of AI and Machine Learning with Pediatric Cardiology
• 5.6 Impact of Drivers and Restraints:

6. US Pediatric Cardiology Market Analysis

• 6.1 US Pediatric Cardiology Market Revenue (US$ Million), 2021-2031

7. US Pediatric Cardiology Market Analysis - by Product Type

• 7.1 Transcatheter Heart Valves
  • 7.1.1 Overview
  • 7.1.2 Transcatheter Heart Valves: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 7.2 Occlusion Devices
  • 7.2.1 Overview
  • 7.2.2 Occlusion Devices: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 7.3 Atherectomy Devices
  • 7.3.1 Overview
  • 7.3.2 Atherectomy Devices: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 7.4 Catheters
  • 7.4.1 Overview
  • 7.4.2 Catheters: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 7.5 Stents
  • 7.5.1 Overview
  • 7.5.2 Stents: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 7.6 Introducer Sheaths
  • 7.6.1 Overview
  • 7.6.2 Introducer Sheaths: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 7.7 Others
  • 7.7.1 Overview
  • 7.7.2 Others: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)

8. US Pediatric Cardiology Market Analysis - by Surgical Procedures

• 8.1 Interventional Procedures
  • 8.1.1 Overview
  • 8.1.2 Interventional Procedures: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 8.2 Heart Rhythm Management Procedures
  • 8.2.1 Overview
  • 8.2.2 Heart Rhythm Management Procedures: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 8.3 Others
  • 8.3.1 Overview
  • 8.3.2 Others: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)

9. US Pediatric Cardiology Market Analysis - by End User

• 9.1 Hospitals
  • 9.1.1 Overview
  • 9.1.2 Hospitals: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 9.2 Specialty Clinics
  • 9.2.1 Overview
  • 9.2.2 Specialty Clinics: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 9.3 Others
  • 9.3.1 Overview
  • 9.3.2 Others: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)

10. US Pediatric Cardiology Market Analysis - by Disease Indication

• 10.1 Patient Foramen Ovale (PFO)
  • 10.1.1 Overview
  • 10.1.2 Patient Foramen Ovale (PFO): US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 10.2 Congenital Heart Disease
  • 10.2.1 Overview
  • 10.2.2 Congenital Heart Disease: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 10.3 Acquired Heart Disease
  • 10.3.1 Overview
  • 10.3.2 Acquired Heart Disease: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 10.4 Arrhythmias
  • 10.4.1 Overview
  • 10.4.2 Arrhythmias: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 10.5 Cardiomyopathies
  • 10.5.1 Overview
  • 10.5.2 Cardiomyopathies: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)
• 10.6 Others
  • 10.6.1 Overview
  • 10.6.2 Others: US Pediatric Cardiology Market - Revenue and Forecast to 2031 (US$ Million)

11. Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in US Pediatric Cardiology Market
• 11.3 Organic Growth Strategies
  • 11.3.1 Overview
• 11.4 Inorganic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 Abbott Laboratories
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Medtronic Plc
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Edwards Lifesciences Corp
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Terumo Corp
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 W L Gore and Associates Inc
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 NuMED
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 Cordis Corp
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 Occlutech US LLC
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 Biotronik SE & Co KG
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments
• 12.10 RENATA MEDICAL
  • 12.10.1 Key Facts
  • 12.10.2 Business Description
  • 12.10.3 Products and Services
  • 12.10.4 Financial Overview
  • 12.10.5 SWOT Analysis
  • 12.10.6 Key Developments

13. Appendix

• 13.1 About The Insight Partners
• 13.2 Glossary of Terms